Novartis today announced that Entresto® (sacubitril/valsartan) has received a new indication in China for the treatment of patients with essential hypertension, a disease affecting approximately 245 million adults in the country¹. This National Medical Products Administration (NMPA) decision follows the 2017 approval of Entresto for the treatment of heart failure with reduced ejection fraction (HFrEF). 

• The prevalence of hypertension in China is expected to rise to approximately 300 million² by 2025 with control rates generally lower than in other parts of …